ABT-869, a promising multi-targeted tyrosine kinase inhibitor: From bench to bedside

由 Zhou, J., Chen, C.-S., Goh, B.-C., Albert, D.H.
出版 2011

ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft

由 Jasinghe, V.J., Xie, Z., Zhou, J., Khng, J., Poon, L.-F., Senthilnathan, P., Chen, C.-S., Albert, D.H., Davidsen, S.K.
出版 2011

Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway

由 Zhou, J., Pan, M., Xie, Z., Loh, S.-L., Bi, C., Tai, Y.-C., Lilly, M., Lim, Y.-P., Han, J.-H., Glaser, K.B., Albert, D.H., Davidsen, S.K., Chen, C.-S.
出版 2014

PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-aml therapy

由 Zhou, J., Bi, C., Chng, W.-J., Cheong, L.-L., Liu, S.-C., Mahara, S., Tay, K.-G., Zeng, Q., Li, J., Guo, K., Tan, C.P.B., Yu, H., Albert, D.H., Chen, C.-S.
出版 2014

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

由 Zhou, J., Bi, C., Janakakumara, J.V., Liu, S.-C., Chng, W.-J., Tay, K.-G., Poon, L.-F., Xie, Z., Palaniyandi, S., Chen, C.-S., Yu, H., Glaser, K.B., Albert, D.H., Davidsen, S.K.
出版 2011

In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor

由 Zhou, J., Khng, J., Jasinghe, V.J., Bi, C., Poon, L.F., Xie, Z., Chen, C.-S., Neo, C.H.S., Pan, M., Yu, H., Yeoh, A.E.-J., Lu, Y., Glaser, K.B., Albert, D.H., Davidsen, S.K.
出版 2011

In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor

由 Zhou, J., Khng, J., Jasinghe, V.J., Bi, C., Poon, L.F., Xie, Z., Chen, C.-S., Neo, C.H.S., Pan, M., Yu, H., Yeoh, A.E.-J., Lu, Y., Glaser, K.B., Albert, D.H., Davidsen, S.K.
出版 2011